I have now read the full thing. I have to say say again first that I am not a lawyer, but it really felt as the judge was placing excessive burden of proof to Amarin vs generics.
IN particular I find very troublesome that she finds 2 of the secondary considerations favoring Amarin and still invalidated the patents.
I simply do not see clearly that defendant has proven that the patent are obvious when everything (including secondary considerations) are evaluated together. I look forward to HDGabor analysis who I have a great respect for, but my own analysis is that Amarin has a significant chance of success on the appeal
News 
Market Data 
Discover 
